Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 340-342

  Rooryck, Caroline ^a   Barnetche, Thomas ^a,b   Richez, Christophe ^b   Laleye, Anatole ^a   Arveiler, Benot̂ ^a   Schaeverbeke, Thierry ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Anti TNF therapy; Pharmacogenetics; Rheumatoid arthritis; SNP

Indexed keywords

CD16 ANTIGEN; CD16A ANTIGEN; INFLIXIMAB; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 43349087111     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)